Advisor Group Inc. Boosts Holdings in Glaukos Corp (NYSE:GKOS)

Advisor Group Inc. grew its holdings in Glaukos Corp (NYSE:GKOS) by 326.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,654 shares of the medical instruments supplier’s stock after acquiring an additional 11,215 shares during the period. Advisor Group Inc.’s holdings in Glaukos were worth $1,148,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also bought and sold shares of the business. Geode Capital Management LLC lifted its position in shares of Glaukos by 14.0% during the 4th quarter. Geode Capital Management LLC now owns 365,226 shares of the medical instruments supplier’s stock worth $20,513,000 after purchasing an additional 44,867 shares during the last quarter. United Services Automobile Association lifted its position in Glaukos by 21.2% in the fourth quarter. United Services Automobile Association now owns 5,940 shares of the medical instruments supplier’s stock valued at $334,000 after acquiring an additional 1,040 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in Glaukos in the fourth quarter valued at $676,000. Rhumbline Advisers lifted its position in Glaukos by 49.5% in the fourth quarter. Rhumbline Advisers now owns 44,801 shares of the medical instruments supplier’s stock valued at $2,516,000 after acquiring an additional 14,828 shares during the last quarter. Finally, Baillie Gifford & Co. lifted its position in Glaukos by 2.0% in the first quarter. Baillie Gifford & Co. now owns 1,759,622 shares of the medical instruments supplier’s stock valued at $137,901,000 after acquiring an additional 34,139 shares during the last quarter. Institutional investors and hedge funds own 95.79% of the company’s stock.

In other news, CFO Joseph E. Gilliam sold 2,603 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $65.14, for a total value of $169,559.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.70% of the stock is currently owned by corporate insiders.

Shares of GKOS opened at $72.94 on Thursday. Glaukos Corp has a 1-year low of $36.89 and a 1-year high of $83.14. The firm has a market capitalization of $2.65 billion, a P/E ratio of -197.14 and a beta of 1.57. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.72 and a quick ratio of 6.23.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, May 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.08. Glaukos had a negative net margin of 5.93% and a negative return on equity of 6.90%. The business had revenue of $54.03 million during the quarter, compared to analysts’ expectations of $50.13 million. As a group, sell-side analysts predict that Glaukos Corp will post -0.3 earnings per share for the current fiscal year.

A number of brokerages recently weighed in on GKOS. Zacks Investment Research cut shares of Glaukos from a “buy” rating to a “hold” rating in a research report on Tuesday, March 12th. BTIG Research reissued a “hold” rating on shares of Glaukos in a research report on Wednesday, May 22nd. Piper Jaffray Companies reissued an “overweight” rating and issued a $80.00 price target on shares of Glaukos in a research report on Thursday, February 28th. Wells Fargo & Co reissued a “buy” rating on shares of Glaukos in a research report on Wednesday, March 20th. Finally, BMO Capital Markets boosted their price target on shares of Glaukos from $66.00 to $71.00 and gave the company a “market perform” rating in a research report on Thursday, May 9th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. Glaukos has an average rating of “Buy” and a consensus price target of $72.56.

TRADEMARK VIOLATION NOTICE: “Advisor Group Inc. Boosts Holdings in Glaukos Corp (NYSE:GKOS)” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2019/06/13/advisor-group-inc-boosts-holdings-in-glaukos-corp-nysegkos.html.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.

Featured Article: How does a margin account work?

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply